Featured Galleries "Holodomor through the eyes of Ukrainian Artists" - Opening of Art Exhibition in Wash, D.C. Ukrainian Federation of America marked its 30th Anniversary USUBC COLLECTION OF OVER 160 UKRAINE HISTORIC NEWS PHOTOGRAPHS HOLODOMOR: THROUGH THE EYES OF UKRAINIAN ARTISTS - COLLECTION OF POSTERS AND PAINTINGS USUBC COLLECTION OF HISTORIC PHOTOGRAPHS ABOUT LIFE AND CAREER OF IGOR SIKORSKY PHOTOGRAPHS - INVENTOR OF THE HELICOPTER Ten USUBC Historic Full Page Ads in the Kyiv Post
ABBOTT LAUNCHES MOLECULAR POINT-OF-CARE TEST TO
DETECT NOVEL CORONAVIRUS IN AS LITTLE AS FIVE MINUTES
Abbott Laboratories, 100 Abbott Park Road,
Chicago, Wed, Apr 1, 2020
- The Abbott ID NOW™ COVID-19 test brings rapid testing to the front lines
- Test to run on Abbott's point-of-care ID NOW platform - a portable instrument that can be deployed where testing is needed most
- ID NOW has the largest molecular point-of-care installed base in the U.S. and is available in a wide range of healthcare settings
- Abbott will be making ID NOW COVID-19 tests available next week and expects to ramp up manufacturing to deliver 50,000 tests per day
- This is the company's second test to receive Emergency Use Authorization by the FDA for COVID-19 detection; combined, Abbott expects to produce about 5 million tests per month
CHICAGO.....Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes. [Abbott is a member of the U.S.-Ukraine Business Council (USUBC), www.usubc.org and has been operating in Ukraine for many years.]
The test will run on the company's ID NOW™ platform, providing rapid results in a wide range of healthcare settings such as physicians' offices, urgent care clinics and hospital emergency departments.
The ID NOW platform is small, lightweight (6.6 pounds) and portable (the size of a small toaster), and uses molecular technology, which is valued by clinicians and scientific community for its high degree of accuracy. ID NOW is already the most widely available molecular point-of-care testing platform in the U.S. today.
"The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus," said Robert B. Ford, president and chief operating officer, Abbott. "With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots."
Abbott will be making ID NOW COVID-19 tests available next week to healthcare providers in urgent care settings in the U.S., where the majority of ID NOW instruments are in use today. The company is working with the Administration to deploy tests to areas where they can have the greatest impact.
The arrival of the Abbott ID NOW COVID-19 test comes a week after the company launched its Abbott m2000™ RealTime SARS-CoV-2 EUA test, which runs on the m2000™ RealTime System located in hospital and reference labs around the world. Between the two platforms, Abbott expects to produce about 5 million tests per month.
About the ID NOW™ Molecular Platform ---------
As the world leader in point-of-care diagnostics, Abbott is adding its expertise and scale to help fight the COVID-19 global pandemic. First introduced in 2014, ID NOW is the leading molecular point-of-care platform for Influenza A & B, Strep A and RSV testing in the U.S.
ID NOW is a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. Its unique isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing clinicians to make evidence-based clinical decisions during a patient visit.
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.
USUBC NOTE: Abbott is a member of U.S.-Ukraine Business Council (USUBC), Wash, D.C., www.USUBC.org, has been operating in Ukraine for many years.
NEWS: For the latest news go to the KYIV POST website: www.KyivPost.com.
The Kyiv Post is a member of the U.S.-Ukraine Business Council (USUBC).
U.S.-Ukraine Business Council (USUBC)
1030 15th Street, N.W., Suite 555 W, Washington, D.C.
Morgan Williams, President & CEO, email@example.com, www.USUBC.org.
Power Corrupts...Absolute Power Corrupts Absolutely.
NOTE: If you would like to unsubscribe from the U.S.-Ukraine Business